Kevin Hern: “When you’re spending at twice the rate of what your revenue growth is, that’s a problem.”

I will always advocate for those who are suffering from a rare disease and support efforts to bring treatments for these diseases to market.

I’ve not heard anyone say they don’t want to cut anything. It’s just that they don’t like Elon.

One way to do this is by reducing the regulatory burden so that Title IV-B funding recipients can spend more time helping children and families, and less time waiting through the red tape.

It is sad that what we are dealing with is stifled innovation and a decrease in patient access due to the Inflation Reduction Act.